Cargando…

Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma

Primary splenic angiosarcoma (PSA) is a rare malignancy with poor prognosis. At present, little study is available on immunotherapy in PSA. Here, we report a case of a patient with metastatic PSA who was treated with programmed death-1 (PD-1) inhibitors and vascular endothelial growth factor (VEGF)...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Weiran, Wang, Kai, Gu, Wenguang, Nie, Xinxin, Zhang, Hao, Tang, Chuanhao, Lin, Li, Liang, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928100/
https://www.ncbi.nlm.nih.gov/pubmed/35311098
http://dx.doi.org/10.3389/fonc.2022.809068
_version_ 1784670581245870080
author Xu, Weiran
Wang, Kai
Gu, Wenguang
Nie, Xinxin
Zhang, Hao
Tang, Chuanhao
Lin, Li
Liang, Jun
author_facet Xu, Weiran
Wang, Kai
Gu, Wenguang
Nie, Xinxin
Zhang, Hao
Tang, Chuanhao
Lin, Li
Liang, Jun
author_sort Xu, Weiran
collection PubMed
description Primary splenic angiosarcoma (PSA) is a rare malignancy with poor prognosis. At present, little study is available on immunotherapy in PSA. Here, we report a case of a patient with metastatic PSA who was treated with programmed death-1 (PD-1) inhibitors and vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors combined therapy and achieved complete response (CR). The patient was a 57−year−old woman with three liver metastases. She was treated with seven cycles of toripalimab plus anlotinib. Programmed death-ligand 1 (PD-L1) immunohistochemistry and next-generation sequencing was performed, and the PD-L1 tumor proportion score was 75%. Finally, she achieved CR after six cycles of the combined therapy regimen. No serious adverse events were detected. To the best of our knowledge, this is the first clinical evidence that anti-PD-1 plus anti-VEGF therapy might be a promising option for patients with metastatic PSA. However, more clinical trials are needed to verify this conclusion.
format Online
Article
Text
id pubmed-8928100
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-89281002022-03-18 Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma Xu, Weiran Wang, Kai Gu, Wenguang Nie, Xinxin Zhang, Hao Tang, Chuanhao Lin, Li Liang, Jun Front Oncol Oncology Primary splenic angiosarcoma (PSA) is a rare malignancy with poor prognosis. At present, little study is available on immunotherapy in PSA. Here, we report a case of a patient with metastatic PSA who was treated with programmed death-1 (PD-1) inhibitors and vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors combined therapy and achieved complete response (CR). The patient was a 57−year−old woman with three liver metastases. She was treated with seven cycles of toripalimab plus anlotinib. Programmed death-ligand 1 (PD-L1) immunohistochemistry and next-generation sequencing was performed, and the PD-L1 tumor proportion score was 75%. Finally, she achieved CR after six cycles of the combined therapy regimen. No serious adverse events were detected. To the best of our knowledge, this is the first clinical evidence that anti-PD-1 plus anti-VEGF therapy might be a promising option for patients with metastatic PSA. However, more clinical trials are needed to verify this conclusion. Frontiers Media S.A. 2022-03-03 /pmc/articles/PMC8928100/ /pubmed/35311098 http://dx.doi.org/10.3389/fonc.2022.809068 Text en Copyright © 2022 Xu, Wang, Gu, Nie, Zhang, Tang, Lin and Liang https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Xu, Weiran
Wang, Kai
Gu, Wenguang
Nie, Xinxin
Zhang, Hao
Tang, Chuanhao
Lin, Li
Liang, Jun
Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma
title Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma
title_full Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma
title_fullStr Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma
title_full_unstemmed Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma
title_short Case Report: Complete Remission With Anti−PD−1 and Anti−VEGF Combined Therapy of a Patient With Metastatic Primary Splenic Angiosarcoma
title_sort case report: complete remission with anti−pd−1 and anti−vegf combined therapy of a patient with metastatic primary splenic angiosarcoma
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8928100/
https://www.ncbi.nlm.nih.gov/pubmed/35311098
http://dx.doi.org/10.3389/fonc.2022.809068
work_keys_str_mv AT xuweiran casereportcompleteremissionwithantipd1andantivegfcombinedtherapyofapatientwithmetastaticprimarysplenicangiosarcoma
AT wangkai casereportcompleteremissionwithantipd1andantivegfcombinedtherapyofapatientwithmetastaticprimarysplenicangiosarcoma
AT guwenguang casereportcompleteremissionwithantipd1andantivegfcombinedtherapyofapatientwithmetastaticprimarysplenicangiosarcoma
AT niexinxin casereportcompleteremissionwithantipd1andantivegfcombinedtherapyofapatientwithmetastaticprimarysplenicangiosarcoma
AT zhanghao casereportcompleteremissionwithantipd1andantivegfcombinedtherapyofapatientwithmetastaticprimarysplenicangiosarcoma
AT tangchuanhao casereportcompleteremissionwithantipd1andantivegfcombinedtherapyofapatientwithmetastaticprimarysplenicangiosarcoma
AT linli casereportcompleteremissionwithantipd1andantivegfcombinedtherapyofapatientwithmetastaticprimarysplenicangiosarcoma
AT liangjun casereportcompleteremissionwithantipd1andantivegfcombinedtherapyofapatientwithmetastaticprimarysplenicangiosarcoma